Briacell Therapeutics Corp Stock Total Debt
| BCTXW Stock | USD 0.51 0.01 2.00% |
BriaCell Therapeutics Corp fundamentals help investors to digest information that contributes to BriaCell Therapeutics' financial success or failures. It also enables traders to predict the movement of BriaCell Stock. The fundamental analysis module provides a way to measure BriaCell Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BriaCell Therapeutics stock.
Total Debt To Capitalization is likely to climb to 0.0005 in 2024. BriaCell | Total Debt |
BriaCell Therapeutics Corp Company Total Debt Analysis
BriaCell Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current BriaCell Therapeutics Total Debt | 8.56 M |
Most of BriaCell Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BriaCell Therapeutics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BriaCell Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for BriaCell Therapeutics is extremely important. It helps to project a fair market value of BriaCell Stock properly, considering its historical fundamentals such as Total Debt. Since BriaCell Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BriaCell Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BriaCell Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
BriaCell Total Debt Historical Pattern
Today, most investors in BriaCell Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BriaCell Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of BriaCell Therapeutics total debt as a starting point in their analysis.
BriaCell Therapeutics Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
BriaCell Net Debt
Net Debt |
|
Based on the latest financial disclosure, BriaCell Therapeutics Corp has a Total Debt of 8.56 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total debt for all United States stocks is notably lower than that of the firm.
BriaCell Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BriaCell Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BriaCell Therapeutics could also be used in its relative valuation, which is a method of valuing BriaCell Therapeutics by comparing valuation metrics of similar companies.BriaCell Therapeutics is currently under evaluation in total debt category among its peers.
BriaCell Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of BriaCell Therapeutics from analyzing BriaCell Therapeutics' financial statements. These drivers represent accounts that assess BriaCell Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BriaCell Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 6.8M | 77.8M | 99.9M | 102.8M | 92.5M | 97.1M | |
| Enterprise Value | 7.0M | 20.6M | 58.8M | 81.5M | 73.4M | 77.0M |
BriaCell Fundamentals
| Return On Equity | -2.06 | ||||
| Return On Asset | -1.26 | ||||
| Number Of Shares Shorted | 2.94 K | ||||
| EBITDA | (4.79 M) | ||||
| Net Income | (4.93 M) | ||||
| Total Debt | 8.56 M | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (24.13 M) | ||||
| Beta | 1.82 | ||||
| Market Capitalization | 48.08 M | ||||
| Total Asset | 5.87 M | ||||
| Retained Earnings | (85.44 M) | ||||
| Working Capital | (3.81 M) | ||||
| Net Asset | 5.87 M |
About BriaCell Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BriaCell Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BriaCell Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BriaCell Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BriaCell Stock Analysis
When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.